RecruitingNot ApplicableNCT07104955

Salutare One Referral Software Impact on Multi-Disciplinary Team (MDT) Meetings Effectiveness and Safety

Single Cohort Before and After Mixed-methods Prospective Study to Investigate the Impact of the Salutare One Referral Software on Patient Outcomes, Safety and Effectiveness of Multi-Disciplinary Team (MDT) Meetings

Sponsor

Salutare Group Ltd.

Enrollment

40 participants

Start Date

Jul 31, 2025

Study Type

INTERVENTIONAL

Conditions

Sarcoma Cancer (Solid Tumors)

Summary

Multi-Disciplinary Team (MDT) meetings are crucial for planning patient care in the National Health Service (NHS), but they can be time-consuming and sometimes lack complete patient information. This can lead to delays in treatment decisions, potentially incomplete care plans, or the need to repeatedly discuss the same patient cases. This study aims to test a new software called Salutare One Referral. One Referral is designed to make these meetings more efficient and effective. We want to see if this software can help healthcare staff prepare MDT referral information more easily and facilitate a more informed MDT discussion, which could lead to better patient care. If successful, this could help improve how MDTs operate across the NHS.

Eligibility

Plain Language Summary

Simplified for easier understanding

This study is evaluating whether a new software tool called Salutare One helps multi-disciplinary medical teams (groups of specialists who meet to discuss complex patient cases) work more efficiently and safely. **You may be eligible if...** - You are a healthcare professional who participates in multi-disciplinary team (MDT) meetings — such as a panel member, coordinator, or staff member who submits referrals - You are willing to participate in the study activities **You may NOT be eligible if...** - You participate in MDT meetings but are unwilling or unable to take part in the study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.